Reuters: Hot Stocks: UPDATE 1-Gilead combo hepatitis C pill shown effective in small trial

Reuters: Hot Stocks Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-Gilead combo hepatitis C pill shown effective in small trial May 2nd 2013, 14:38 Thu May 2, 2013 10:38am EDT (Adds analyst comment, details on trial, hepatitis C) By Ransdell Pierson May 2 (Reuters) - Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have eliminated the liver virus after either 8 weeks or 12 weeks of treatment in a small mid-stage study. The data could help Gilead, whose shares rose 4.5 percent, remain in the lead among drugmakers racing to develop better medicines for the potentially dangerous condition that also require far shorter durations of treatment. Based on the favorable interim data from the trial of 60 previously untreated patients, named LONESTAR, Gilead said it plans to conduct a third late-stage study of the once-daily fixed-dose combination tablet. It pairs the drugs sofosbuvir and ledipasvir. The new Phase III trial, called ION-3, will enroll 600 patients new to treatment who have the most common genotype 1 form of hepatitis C, Gilead said. It will evaluate the combination tablet for eight weeks of treatment, with and without another oral antiviral drug called ribavirin that is a mainstay of current standard treatments. The trial will also test the combination drug for 12 weeks, without ribavirin. Gilead said all 19 patients in the LONESTAR trial who took the combo pill for 12 weeks had a sustained virologic response (SVR), meaning they had no detectable signs of the virus, as assessed by blood tests given four weeks after completing therapy. Moreover, the company said 40 of 41 patients who took the tablet for eight weeks were deemed free of the virus eight weeks after they completed treatment. Gilead said one patient relapsed, and that patient was from a group that took the combo tablet but did not take ribavirin. "We believe this data greatly strengthens Gilead's position in the hepatitis C market, with an all oral once-daily pill across all genotype 1 patients and potentially for only 8 weeks" of treatment, ISI Group analyst Mark Schoenebaum said in a research report. Hepatitis C affects an estimated 170 million people worldwide, and if left untreated can lead to cirrhosis, liver cancer or the need for a new liver. Current treatments include use of interferon, an injectable drug that causes flu like symptoms. Wall Street expects any approved oral regimen for hepatitis C to garner billions of dollars in annual sales. (Reporting By Ransdell Pierson; Editing by Gerald E. McCormick and Nick Zieminski) Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions